Annovis Bio Inc ((ANVS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Annovis Bio Inc. is conducting a clinical trial titled A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer’s Disease. The study aims to evaluate the efficacy and safety of the drug buntanetap/Posiphen in improving cognition and function in adults aged 55-85 with early Alzheimer’s disease.
The intervention being tested is a drug named buntanetap/Posiphen, administered as a 30mg capsule taken orally once daily for 18 months. The purpose is to assess its potential to treat early Alzheimer’s disease compared to a placebo.
This Phase 3 study is interventional, with participants randomly allocated to either the experimental drug group or a placebo group. It follows a parallel intervention model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary goal is treatment-focused.
The study began on November 26, 2024, with primary completion expected by August 27, 2025, which is also the date of the last update. These dates are crucial for tracking progress and anticipating results.
The outcome of this study could significantly influence Annovis Bio Inc.’s stock performance and investor sentiment, especially if the results show positive efficacy and safety. In the competitive Alzheimer’s treatment market, successful trials can set a company apart, potentially leading to increased market share and investor interest.
The study is currently ongoing, with further details available on the ClinicalTrials portal.